Comparison · NCT01349972-43709ac3
Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) vs Arm II (Cytarabine, Daunorubicin Hydrochloride): Number of Patients With Minimal Residual Disease
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) vs Arm II (Cytarabine, Daunorubicin Hydrochloride): Number of Patients With Minimal Residual Disease. Trial comparisons, record NCT01349972-43709ac3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01349972-43709ac3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.255 | 0.18 | 0.347 | wilson | |
| Risk in group 2 | 0.436 | 0.314 | 0.567 | wilson | |
| Risk difference, group 1 minus group 2 | -0.181 | -0.332 | -0.0279 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.584 | 0.373 | 0.914 | log | |
| Odds ratio, group 1 over group 2 | 0.442 | 0.221 | 0.885 | log | |
| Number needed to treat, for one fewer participant with the outcome on Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) than on Arm II (Cytarabine, Daunorubicin Hydrochloride) | 5.51 | 3.01 | 35.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) | Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Patients who achieve complete or partial response to the first course (completion of all doses) may receive a second course of treatment or high-dose cytarabine after 21-63 days following blood count recovery, and/or undergo allogeneic bone marrow transplant.~alvocidib: Given IV~mitoxantrone hydrochloride: Given IV~cytarabine: Given IV | 26 | 102 | OG000 |
| Group 2 | Arm II (Cytarabine, Daunorubicin Hydrochloride) | Patients receive cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients who have residual disease on day 14 may receive additional cytarabine for 5 days and daunorubicin hydrochloride for 2 days.~daunorubicin hydrochloride: Given IV~cytarabine: Given IV | 24 | 55 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients With Minimal Residual Disease
- Description
- Comparisons of the treatments with respect to MRD will be based on the number of patients with MRD at day 14 after the start of treatment.
- Time frame
- From study start to 14 days after the start of treatment
- Population
Source ClinicalTrials.gov
Trial
- Title
- Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- NCT number
- NCT01349972
- Phases
- PHASE2
- Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- alvocidib, daunorubicin hydrochloride, mitoxantrone hydrochloride, cytarabine
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2017-06-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01349972?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01349972-43709ac3